retatrutide triple agonist glp-1 gip glucagon phase 3 2025 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials From Obesity to Metabolic Health:

This is not standard practice but is worth discussing with a healthcare provider if tolerability is a problem

If you dropped 2 pounds total in four weeks, that's normal too especially if you started at a lower dose

Wu T, Horo witz M, Rayner CK: New insights into the anti-diabetic actions of metformin: from the liver to the gut

Since this may be expensive, though, it may create a barrier for companies to explore this option

PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 14 metabolic pathways and 150+ genetic insights, including your GLP1R, GIPR, FTO, and MC4R variants

Synthesized in the intestinal L-cells, GLP-1 is secreted in response to food intake, stimulating insulin secretion and inhibiting glucagon release [1]